Related Experiment Video
Updated: Aug 14, 2026
Genetic Manipulation in Δku80 Strains for Functional Genomic Analysis of Toxoplasma gondii
Published on: July 12, 2013
Identification and characterisation of Toxoplasma gondii protein farnesyltransferase
M Ibrahim1, N Azzouz, P Gerold
1Zentrum für Hygiene und Medizinische Mikrobiologie, Philipps-Universität Marburg, Robert-Koch-Strasse 17, 35037 Marburg, Germany.
Abstract:
Prenylated proteins are involved in the regulation of DNA replication and cell cycling and have important roles in the regulation of cell proliferation. Protein farnesyltransferase and protein geranylgeranyltransferase are the two enzymes responsible for catalysing isoprene lipid modifications. Recently these enzymes have been targets for the development of cancer chemotherapeutics. Using metabolic labelling we identified isoprenylated proteins which suggests the presence of protein farnesyltransferase in Toxoplasma gondii. T. gondii protein farnesyltransferase is heat-labile and requires Mg(2+) and Zn(2+) ions for full activity. Peptidomimetic analogues as well as short synthetic peptides were tested in vitro as possible competitors for farnesyltransferase substrates. We found that the synthetic peptide (KTSCVIA) specifically inhibited T. gondiiprotein farnesyltransferase but not mammalian (HeLa cells) farnesyltransferase. Therefore this study suggests the possible development of specific inhibitors of T. gondiiprotein farnesyltransferase as an approach to parasitic protozoa therapy.
Insights
Researchers identified a specific inhibitor for Toxoplasma gondii protein farnesyltransferase, a key enzyme in parasitic protozoa. This finding suggests a novel therapeutic strategy for treating parasitic infections by targeting this enzyme.
Area of Science:
- Biochemistry
- Parasitology
- Drug Discovery
Background:
- Prenylated proteins regulate crucial cellular processes like DNA replication and proliferation.
- Protein farnesyltransferase (PFT) and protein geranylgeranyltransferase are key enzymes in lipid modification.
- These enzymes are actively explored as targets for cancer chemotherapeutics.
Purpose of the Study:
- To investigate the presence and characteristics of PFT in Toxoplasma gondii.
- To identify potential inhibitors of T. gondii PFT for therapeutic applications.
Main Methods:
- Metabolic labeling was used to identify isoprenylated proteins in T. gondii.
- Enzyme activity assays were performed to characterize T. gondii PFT.
- In vitro inhibition assays were conducted using synthetic peptides and peptidomimetics.
Main Results:
- The study confirmed the presence of heat-labile PFT in T. gondii, requiring Mg(2+) and Zn(2+) for activity.
- A synthetic peptide, KTSCVIA, was identified as a specific inhibitor of T. gondii PFT.
- This peptide did not inhibit mammalian PFT from HeLa cells, demonstrating target specificity.
Conclusions:
- T. gondii possesses a unique protein farnesyltransferase that can be specifically inhibited.
- The synthetic peptide KTSCVIA shows potential as a lead compound for developing novel anti-parasitic therapies.
- Targeting T. gondii PFT offers a promising avenue for treating parasitic protozoa infections.
More Related Videos
11:21Forward Genetics Screens Using Macrophages to Identify Toxoplasma gondii Genes Important for Resistance to IFN-γ-Dependent Cell Autonomous Immunity
Published on: March 12, 2015
11:37QTL Mapping and CRISPR/Cas9 Editing to Identify a Drug Resistance Gene in Toxoplasma gondii
Published on: June 22, 2017
